By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Achillion Pharmaceuticals, Inc. 

300 George Street

New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-7000 Fax: 203-624-7003


SEARCH JOBS


Industry
Pharmaceutical

Segment
Drug Discovery





Company News
Achillion (ACHN) Announces 100% SVR12 In The 6-Week And 8-Week Cohorts In Janssen’s Phase II Trial Evaluating The Triple Combination Treatment Regimen Including Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naïve HCV 9/26/2016 7:30:19 AM
Achillion (ACHN), Johnson & Johnson (JNJ)'s Hep C Candidate Scores a 100% Cure Rate in Phase IIa Trial 9/9/2016 5:46:17 AM
Achillion (ACHN) Presents Novel Research On Factor D Inhibition At The XXVIth International Complement Workshop 9/6/2016 8:11:41 AM
Achillion (ACHN) To Present At Two Upcoming Investor Conferences 9/1/2016 8:01:55 AM
Achillion (ACHN) Announces Upcoming Presentation Of Interim Phase IIa Results From The Janssen Pharmaceutical Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference 8/11/2016 10:54:21 AM
Achillion (ACHN) To Present At The 2016 Wedbush Pacgrow Healthcare Conference 8/9/2016 8:42:52 AM
Achillion (ACHN) Reports Second Quarter 2016 Financial Results 8/5/2016 8:47:02 AM
10 Biotech Stocks that Could Blow Up in Q3 7/6/2016 6:56:11 AM
Achillion (ACHN) Presents Interim Phase I Results For ACH-4471, A Novel Orally-Administered Factor D Inhibitor, At The 21st Congress Of The European Hematology Association 6/10/2016 7:29:48 AM
Achillion (ACHN) To Present At Three Upcoming Investor Conferences 6/2/2016 10:26:33 AM
12345678910...
//-->